Daewoong Pharmaceutical Acquires Licensor Status for mRNA-based ERA Platform
- Daewoong Pharmaceutical's subsidiary acquires licensor status for Turn Bio's mRNA-based ERA platform for up to USD 239M (upfront $1M, milestones $238M, royalties separate).
- It succeeds the rights and obligations of the original joint development and license agreement with Hanall Biopharma, securing rights to receive milestones and royalties from Hanall.
- The acquisition was won as the highest bidder in a live auction on May 6, 2026 in the US; final succession agreement expected by end of May.
- This is a conditional contract; revenue recognition depends on clinical and regulatory success; contract may terminate if development stops.
- Contract effective upon conditions being met; termination date is later of 10 years after first commercial sale, patent expiry, or exclusivity expiry.
ADVERTISEMENT (250px+)
KOSPI Filing Information
- Filing: Major Management Matters Related to Investment Decision (Major Management Matters of Subsidiary) (Succession of Technology Transfer Agreement Status for mRNA-based Epigenetic Reprogramming of Aging (ERA))
- Company: Daewoong (003090)
- Submission: Daewoong Co., Ltd.
- Receipt: 05-07-2026
- Under KRX KOSPI Market Division